Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 8/20 | 0.47 |
| ▸ | DDB1 | Q16531 | 7/20 | 0.47 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.42 |
| ▸ | BACE1 | P56817 | 3/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.40 |
| ▸ | JAK3 | P52333 | 1/20 | 0.40 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.39 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.39 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27349010 | 1.00 | CRBN (0.47) | CRBNDDB1PDK2ALDH1A1LMNA | |
| SCHEMBL30952388 | 0.85 | DDB1 (0.50) | CRBNDDB1PDK2ALDH1A1LMNA | |
| SCHEMBL24607686 | 0.84 | CYP11B2 (0.43) | CRBNDDB1PDK2ALDH1A1LMNA | |
| SCHEMBL29751386 | 0.84 | CYP11B2 (0.43) | CRBNDDB1PDK2ALDH1A1LMNA | |
| SCHEMBL29265203 | 0.84 | CRBN (0.55) | CRBNDDB1PDK2ALDH1A1LMNA | |
| SCHEMBL30525413 | 0.84 | CRBN (0.55) | CRBNDDB1PDK2ALDH1A1LMNA | |
| SCHEMBL31202060 | 0.83 | DDB1 (0.49) | CRBNDDB1MAPTGPR119NAMPT | |
| SCHEMBL29223677 | 0.83 | DDB1 (0.49) | CRBNDDB1MAPTGPR119NAMPT | |
| SCHEMBL31630927 | 0.82 | DDB1 (0.49) | CRBNDDB1PDK2ALDH1A1LMNA | |
| SCHEMBL30643667 | 0.82 | DDB1 (0.49) | CRBNDDB1PDK2ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240368159-A1 | HPK1 DEGRADERS, COMPOSITIONS COMPRISING THE HPK1 DEGRADER, AND METHODS OF USING THE SAME | BIOFRONT LTD (KY) | 2024-11-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240368159-A1 | HPK1 DEGRADERS, COMPOSITIONS COMPRISING THE HPK1 DEGRADER, AND METHODS OF USING THE SAME | HYPK, PGK1, HIPK1 | CRBN 688/4885DDB1 1230/4885PDK2 94/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.